Waldemar Halota

4.0k total citations · 2 hit papers
88 papers, 1.9k citations indexed

About

Waldemar Halota is a scholar working on Hepatology, Epidemiology and Immunology. According to data from OpenAlex, Waldemar Halota has authored 88 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Hepatology, 62 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Waldemar Halota's work include Hepatitis C virus research (56 papers), Hepatitis B Virus Studies (50 papers) and Liver Disease Diagnosis and Treatment (43 papers). Waldemar Halota is often cited by papers focused on Hepatitis C virus research (56 papers), Hepatitis B Virus Studies (50 papers) and Liver Disease Diagnosis and Treatment (43 papers). Waldemar Halota collaborates with scholars based in Poland, United States and Canada. Waldemar Halota's co-authors include Małgorzata Pawłowska, Ching‐Lung Lai, Uchenna H. Iloeje, Samuel S. Lee, Ting‐Tsung Chang, Hui Zhang, Yun‐Fan Liaw, S. P. Beebe, R. Hindes and Zachary Goodman and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Waldemar Halota

86 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡

2010 735 citations Ting‐Tsung Chang, Ching‐Lung Lai et al. Hepatology profile →
Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B

2010 444 citations Ting‐Tsung Chang, Ching‐Lung Lai et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Waldemar Halota Poland	16	1.6k	1.6k	150	112	69	88	1.9k
Hakan Bozkaya Türkiye	25	1.7k 1.0×	1.6k 1.0×	129 0.9×	119 1.1×	29 0.4×	83	2.1k
Karin Neukam Spain	19	770 0.5×	891 0.6×	262 1.7×	78 0.7×	102 1.5×	79	1.3k
Giovanni Ricci Italy	14	888 0.5×	907 0.6×	143 1.0×	109 1.0×	92 1.3×	29	1.3k
S. Beinhardt Austria	19	941 0.6×	1.1k 0.7×	105 0.7×	99 0.9×	125 1.8×	47	1.5k
Cristiane Alves Villela‐Nogueira Brazil	21	1.4k 0.9×	888 0.6×	109 0.7×	184 1.6×	35 0.5×	94	1.7k
Margaret C. Shuhart United States	21	759 0.5×	857 0.5×	141 0.9×	213 1.9×	46 0.7×	32	1.6k
Richard Sallie United States	21	1.4k 0.9×	1.4k 0.9×	296 2.0×	241 2.2×	136 2.0×	48	2.4k
Kelly Kaita Canada	19	887 0.5×	756 0.5×	97 0.6×	111 1.0×	56 0.8×	49	1.2k
Jonathan Booth United Kingdom	16	902 0.6×	735 0.5×	65 0.4×	190 1.7×	80 1.2×	33	1.5k
Gerald Minuk Canada	5	2.0k 1.2×	2.0k 1.3×	168 1.1×	98 0.9×	212 3.1×	8	2.3k

Countries citing papers authored by Waldemar Halota

Since Specialization

Citations

This map shows the geographic impact of Waldemar Halota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Waldemar Halota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Waldemar Halota more than expected).

Fields of papers citing papers by Waldemar Halota

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Waldemar Halota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Waldemar Halota. The network helps show where Waldemar Halota may publish in the future.

Co-authorship network of co-authors of Waldemar Halota

This figure shows the co-authorship network connecting the top 25 collaborators of Waldemar Halota. A scholar is included among the top collaborators of Waldemar Halota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Waldemar Halota. Waldemar Halota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Piekarska, Anna, Krzysztof Tomasiewicz, Waldemar Halota, et al.. (2020). Searching for the optimal population for hepatitis C virusscreening in Poland. Clinical and Experimental Hepatology. 6(2). 74–76. 7 indexed citations

Tomasiewicz, Krzysztof, Anita Olczak, Magdalena Tudrujek‐Zdunek, et al.. (2019). Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals. British Journal of Biomedical Science. 76(4). 190–194. 9 indexed citations

Serafin, Zbigniew, et al.. (2019). Monoexponential and Biexponential Fitting of Diffusional Magnetic Resonance Imaging Signal Analysis for Prediction of Liver Fibrosis Severity. Journal of Computer Assisted Tomography. 43(6). 857–862. 4 indexed citations

Domagalski, Krzysztof, et al.. (2016). Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World Journal of Gastroenterology. 22(41). 9186–9186. 13 indexed citations

Pawłowska, Małgorzata, et al.. (2016). Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents – A Longitudinal Study in Real Life. PLoS ONE. 11(9). e0163691–e0163691. 4 indexed citations

Halota, Waldemar, Robert Flisiak, Anna Boroń‐Kaczmarska, et al.. (2015). Recommendations for the treatment of hepatitis C Polish group of HCV Experts--2015.. PubMed. 69(3). 515–31. 4 indexed citations

Kozielewicz, Dorota, et al.. (2015). Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment. Hepatology International. 10(2). 302–309. 2 indexed citations

Domagalski, Krzysztof, Małgorzata Pawłowska, Dorota Kozielewicz, et al.. (2015). The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. PLoS ONE. 10(6). e0130899–e0130899. 13 indexed citations

Halota, Waldemar, et al.. (2014). Distribution of HCV Genotypes in the Populations of Inmates in Polish Prison Potulice and Patients Hospitalised in Bydgoszcz. Hepatitis Monthly. 14(4). e14559–e14559. 5 indexed citations

10.

Domagalski, Krzysztof, Małgorzata Pawłowska, Andrzej Tretyn, et al.. (2013). Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. Hepatitis Monthly. 13(11). e13678–e13678. 16 indexed citations

11.

Kozielewicz, Dorota, Waldemar Halota, & Dorota Dybowska. (2012). [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].. PubMed. 66(1). 49–54. 3 indexed citations

12.

Pawłowska, Małgorzata, et al.. (2012). Hematological Adverse Events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepatitis Monthly. 11(12). 968–974. 6 indexed citations

13.

Juszczyk, Jacek, Anna Boroń‐Kaczmarska, Janusz Cianciara, et al.. (2010). [Therapeutic recommendations for year 2010: antiviral treatment of chronic HBV infection].. PubMed. 64(1). 81–2. 1 indexed citations

14.

Domagalski, Krzysztof, Andrzej Tretyn, Małgorzata Pawłowska, Joanna Szczepanek, & Waldemar Halota. (2010). [Action of type III IFNs and their roles in immune responses].. PubMed. 64. 522–33. 6 indexed citations

15.

Chang, Ting‐Tsung, Ching‐Lung Lai, Seung Kew Yoon, et al.. (2010). Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B. Hepatology. 51(2). 422–430. 444 indexed citations breakdown →

16.

Pawłowska, Małgorzata & Waldemar Halota. (2007). [Rapid viral response during treatment of chronic hepatitis B with pegylated interferon alfa-2a in children--preliminary report].. PubMed. 61(3). 427–31. 1 indexed citations

17.

Borkowska, Alina, et al.. (2007). Chronic Paranoid Psychosis and Dementia Following Interferon-α Treatment of Hepatitis C: A Case Report. Pharmacopsychiatry. 40(4). 146–148. 6 indexed citations

18.

Wood, Robin, Andrzej Horban, Marek Beniowski, et al.. (2004). Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. AIDS. 18(4). 631–640. 7 indexed citations

19.

Halota, Waldemar, Barbara Jaruga, & Małgorzata Pawłowska. (2002). [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].. PubMed. 13(74). 126–8. 9 indexed citations

20.

Gajda, Anna, et al.. (1978). [Tuberculin reactions in patients with acute viral hepatitis (author's transl)].. PubMed. 35(2). 287–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact